**FRITS**

**EFFICACY**

**Table : TYPE OF IMAGING AT 12-MONTH FOLLOW-UP (CORELAB) [ITT - N=136 patients]**

|  | | **FRED / FRED Jr N=87** | **FRED X N=49** | **Total N=136** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Type of imaging at 12 months** | N | 87 |  | 87 |
|  | Missing data | 0 |  | 0 |
|  | Angiography (DSA) | 68 (78.2%) | 36 (73.5%) | 104 (76.5%) |
|  | Magnetic resonance angiography (MRA) | 18 (20.7%) | 12 (24.5%) | 30 (22.1%) |
|  | Angio-scanner (CTA) | 1 (1.1%) | 1 (2.0%) | 2 (1.5%) |
|  | Between group test |  |  | 0.776 (Fisher) |

**FRITS**

**EFFICACY**

**Table : TIME OF IMAGING AT 12-MONTH FOLLOW-UP (CORELAB) [ITT - N=136 patients]**

|  | | **FRED / FRED Jr N=87** | **FRED X N=49** | **Total N=136** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Time of imaging at 12 months** | N | 87 | 49 | 136 |
|  | DM | 0 | 0 | 0 |
|  | Moyenne (e.t.) | 12.43 (1.72) | 13.35 (3.77) | 12.76 (2.67) |
|  | Médiane | 12.12 | 12.35 | 12.18 |
|  | Q1 - Q3 | 11.72 - 13.23 | 11.92 - 13.60 | 11.84 - 13.46 |
|  | Min - Max | 5.98 - 17.87 | 2.76 - 27.36 | 2.76 - 27.36 |
|  | Test inter-groupes |  |  | 0.121 (Wilcoxon) |

**FRITS**

**EFFICACY**

**Table : TYPE OF IMAGING AT 12-MONTH FOLLOW-UP (CORELAB) [PP - N=124 patients]**

|  | | **FRED / FRED Jr N=79** | **FRED X N=45** | **Total N=124** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Type of imaging at 12 months** | N | 79 |  | 79 |
|  | Missing data | 0 |  | 0 |
|  | Angiography (DSA) | 63 (79.7%) | 32 (71.1%) | 95 (76.6%) |
|  | Magnetic resonance angiography (MRA) | 15 (19.0%) | 12 (26.7%) | 27 (21.8%) |
|  | Angio-scanner (CTA) | 1 (1.3%) | 1 (2.2%) | 2 (1.6%) |
|  | Between group test |  |  | 0.451 (Fisher) |

**FRITS**

**EFFICACY**

**Table : TIME OF IMAGING AT 12-MONTH FOLLOW-UP (CORELAB) [PP - N=124 patients]**

|  | | **FRED / FRED Jr N=79** | **FRED X N=45** | **Total N=124** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Time of imaging at 12 months** | N | 79 | 45 | 124 |
|  | DM | 0 | 0 | 0 |
|  | Moyenne (e.t.) | 12.56 (1.60) | 13.36 (3.91) | 12.85 (2.69) |
|  | Médiane | 12.12 | 12.35 | 12.18 |
|  | Q1 - Q3 | 11.76 - 13.30 | 11.92 - 13.60 | 11.84 - 13.46 |
|  | Min - Max | 8.34 - 17.87 | 2.76 - 27.36 | 2.76 - 27.36 |
|  | Test inter-groupes |  |  | 0.198 (Wilcoxon) |

**FRITS**

**EFFICACY**

**Table : TYPE OF IMAGING AT 12-MONTH FOLLOW-UP (CORELAB) [FAS - N=130 patients]**

|  | | **FRED / FRED Jr N=82** | **FRED X N=48** | **Total N=130** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Type of imaging at 12 months** | N | 82 |  | 82 |
|  | Missing data | 0 | 2 | 2 |
|  | Angiography (DSA) | 65 (79.3%) | 33 (71.7%) | 98 (76.6%) |
|  | Magnetic resonance angiography (MRA) | 16 (19.5%) | 12 (26.1%) | 28 (21.9%) |
|  | Angio-scanner (CTA) | 1 (1.2%) | 1 (2.2%) | 2 (1.6%) |
|  | Between group test |  |  | 0.510 (Fisher) |

**FRITS**

**EFFICACY**

**Table : TIME OF IMAGING AT 12-MONTH FOLLOW-UP (CORELAB) [FAS - N=130 patients]**

|  | | **FRED / FRED Jr N=82** | **FRED X N=48** | **Total N=130** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Time of imaging at 12 months** | N | 82 | 46 | 128 |
|  | DM | 0 | 2 | 2 |
|  | Moyenne (e.t.) | 12.58 (1.74) | 13.36 (3.87) | 12.86 (2.71) |
|  | Médiane | 12.09 | 12.40 | 12.18 |
|  | Q1 - Q3 | 11.72 - 13.30 | 11.92 - 13.60 | 11.79 - 13.46 |
|  | Min - Max | 8.34 - 18.56 | 2.76 - 27.36 | 2.76 - 27.36 |
|  | Test inter-groupes |  |  | 0.155 (Wilcoxon) |